C4 Therapeutics Files 8-K, Material Agreement Details
Ticker: CCCC · Form: 8-K · Filed: 2026-04-09T07:07:35-04:00
Sentiment: neutral
Topics: material-agreement, corporate-update
TL;DR
C4Tx filed an 8-K for a material agreement - check the exhibits for deets.
AI Summary
On April 9, 2026, C4 Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as a corporate deck, indicating potential business developments or updates. Specific financial figures or counterparty names were not detailed in the provided filing summary.
Why It Matters
This filing signals a significant business development for C4 Therapeutics, potentially involving new partnerships, acquisitions, or strategic shifts that could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details in the summary necessitates a medium risk assessment.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001628280-26-024336 (other) — SEC Accession Number for the filing
- 2026-04-09 (date) — Filing Date and Period of Report
FAQ
What is the nature of the material definitive agreement filed by C4 Therapeutics?
The filing indicates Item 1.01: Entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the summary.
What information is contained in the exhibits attached to the 8-K filing?
The exhibits include an iXBRL 8-K, EX-99.1, and a corporate deck (EX-99.2) along with several graphic files, suggesting business or financial updates.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-09 at 07:07:35.
What are the main items disclosed in this 8-K filing?
The main items disclosed are Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
Does the filing provide specific financial figures related to the material agreement?
The provided summary of the 8-K filing does not contain specific financial figures related to the material agreement.
From the Filing
EDGAR Filing Documents for 0001628280-26-024336 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001628280-26-024336 Filing Date 2026-04-09 Accepted 2026-04-09 07:07:35 Documents 40 Period of Report 2026-04-09 Items Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K cccc-20260409.htm iXBRL 8-K 38852 2 EX-99.1 cccc-20260409xexx991.htm EX-99.1 15114 3 EX-99.2 aprilcorporatedeck_final.htm EX-99.2 37876 7 aprilcorporatedeck_final001.jpg GRAPHIC 74625 8 aprilcorporatedeck_final002.jpg GRAPHIC 179004 9 aprilcorporatedeck_final003.jpg GRAPHIC 119699 10 aprilcorporatedeck_final004.jpg GRAPHIC 125185 11 aprilcorporatedeck_final005.jpg GRAPHIC 86218 12 aprilcorporatedeck_final006.jpg GRAPHIC 97988 13 aprilcorporatedeck_final007.jpg GRAPHIC 127078 14 aprilcorporatedeck_final008.jpg GRAPHIC 68208 15 aprilcorporatedeck_final009.jpg GRAPHIC 101925 16 aprilcorporatedeck_final010.jpg GRAPHIC 119781 17 aprilcorporatedeck_final011.jpg GRAPHIC 114762 18 aprilcorporatedeck_final012.jpg GRAPHIC 96169 19 aprilcorporatedeck_final013.jpg GRAPHIC 144727 20 aprilcorporatedeck_final014.jpg GRAPHIC 116650 21 aprilcorporatedeck_final015.jpg GRAPHIC 122192 22 aprilcorporatedeck_final016.jpg GRAPHIC 139152 23 aprilcorporatedeck_final017.jpg GRAPHIC 114800 24 aprilcorporatedeck_final018.jpg GRAPHIC 84242 25 aprilcorporatedeck_final019.jpg GRAPHIC 119141 26 aprilcorporatedeck_final020.jpg GRAPHIC 131779 27 aprilcorporatedeck_final021.jpg GRAPHIC 67887 28 aprilcorporatedeck_final022.jpg GRAPHIC 122781 29 aprilcorporatedeck_final023.jpg GRAPHIC 115806 30 aprilcorporatedeck_final024.jpg GRAPHIC 100493 31 aprilcorporatedeck_final025.jpg GRAPHIC 111926 32 aprilcorporatedeck_final026.jpg GRAPHIC 145713 33 c4tlogo1.jpg GRAPHIC 8913 Complete submission text file 0001628280-26-024336.txt 4308825 Data Files Seq Description Document Type Size 4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20260409.xsd EX-101.SCH 1829 5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20260409_lab.xml EX-101.LAB 22548 6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20260409_pre.xml EX-101.PRE 13088 43 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20260409_htm.xml XML 2915 Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700 C4 Therapeutics, Inc. (Filer) CIK : 0001662579 (see all company filings) EIN. : 475617627 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 26849797 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)